Jonathan I. Lieber, Chief Financial Officer of Rallybio Corp, filed a Form 4 on November 2, 2026, reporting the exercise of two stock options on October 29, 2026, covering a combined 21,464 shares of common stock.

Key Highlights

  • Two option exercises: Lieber exercised options for 7,875 shares at $14.88 and 13,589 shares at $6.08, both on October 29, 2026.
  • Accelerated vesting: Both options had their vesting accelerated in full on October 26, 2026, under the Company's 2021 Equity Incentive Plan, according to the filing.
  • Post-transaction ownership: Following the transactions, Lieber directly held 37,015 shares of common stock, per the filing.
  • Transaction codes: Both transactions were coded "M," indicating exercises of in-the-money or at-the-money derivative securities.
  • Derivative securities reduced to zero: Both options reported zero remaining derivative securities beneficially owned following the transactions.

Lieber Exercises Two Accelerated Options at Rallybio Corp

According to the Form 4 filed with the SEC on November 2, 2026, Jonathan I. Lieber, Chief Financial Officer of Rallybio Corp (NASDAQ:RLYB), reported two option exercises on October 29, 2026. The first involved 7,875 shares of common stock acquired through an option with an exercise price of $14.88, originally set to expire on February 15, 2034. The second involved 13,589 shares acquired through an option with an exercise price of $6.08, originally set to expire on February 14, 2035.

The filing discloses that both options were granted under Rallybio Corp's 2021 Equity Incentive Plan. On October 26, 2026, the vesting of each option "was accelerated in full," and each "became fully vested and exercisable as of that date," according to the explanations included in the filing. The price of each derivative security at the time of exercise is listed as $0.

Following the first exercise, the filing shows Lieber held 23,426 shares directly. Following the second exercise, his directly held position stood at 37,015 shares. Both remaining derivative security positions were reported as zero following the respective transactions. The form was filed by Lieber as one reporting person and was signed on November 2, 2026.

What Was Disclosed

Rallybio Corp's CFO Jonathan I. Lieber disclosed the exercise of two stock options on October 29, 2026, covering 21,464 total shares, with both options having undergone full vesting acceleration on October 26, 2026, under the company's 2021 Equity Incentive Plan.